Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients

AIDS

Volumn 14, Issue 16, 2000, Pages 2567-2574

  Bucciardini, Raffaella ^a   Wu, Albert W ^b   Floridia, Marco ^a   Fragola, Vincenzo ^a   Ricciardulli, Daniela ^a   Tomino, Carlo ^a   Weimer, Liliana E ^a   Pirillo, Maria F ^a   Mirra, Marco ^a   Marzi, Massimo ^a   Giannini, Giacomo ^a   Galluzzo, Clementina M ^a   Andreotti, Mauro ^a   Massella, Maurizio ^a   Vella, Stefano ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Clinical trials; HIV treatments; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0033730383     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00020     Document Type: Article

References (17)

1. Beyond HIV viral load testing
2. A randomized, double blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
3. A health status questionnaire using 30 items from the Medical Outcomes Study: Preliminary validation in persons with early HIV infection
4. Application of Medical Outcomes Study health-related quality of life measures in HIV/AIDS
5. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study Health Survey
6. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV)
7. Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey
8. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection
9. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS
10. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group
11. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavirzidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group
12. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir-zalcitabine therapy for advanced HIV-infected adults with CD4 counts between 50 and 300 per cubic millimeter
13. The sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-report
14. A randomised, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
15. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
16. A double-blind, placebo-controlled study to asses the safety, tolerability and antiretroviral activity of efavirenz in combination with open-label zidovudine and lamivudine in HIV-1 infected patients (DMP 266-004)
17. A phase II, double-blind, placebo-control, dose-ranging study to asses the antiretroviral activity and safety of efavirenz in combination with open-label zidovudine - Lamivudine at > 48 weeks (DMP 266-005)